Research Programs: Cancer Detection, Treatment and Survivorship, Women's Cancer
Assistant Professor, Department of Obstetrics and Gynecology

ghebr004@umn.edu
612-626-3111 — office
Preferred method of contact: e-mail

Dr. Ghebre's clinical profile
(University of Minnesota Physicians Web site)

Dr. Rahel Ghebre is an assistant professor in the Division of Gynecologic Oncology within the Department of Obstetrics, Gynecology and Women's Health. Her clinical practice involves caring for women with ovarian, endometrial, cervical, vulvar and vaginal cancer at the University of Minnesota Women's Health Clinic. Dr. Ghebre is the gynecologic specialist for the University of Minnesota Fanconi Anemia Comprehensive Care program and is board certified in gynecologic oncology in addition to obstetrics and gynecology.

Dr. Ghebre received her M.D. degree at the University of Michigan. She completed her residency in obstetrics and gynecology, and fellowship in gynecologic-oncology at the University of Minnesota in 2004. She then joined as a faculty member in the Division of Gynecologic Oncology in 2005. Dr. Ghebre is board certified in obstetrics and gynecology. Dr. Ghebre was an NIH BIRCWH (Building Interdisciplinary Research Careers in Women's Health Scholar.

Dr. Ghebre's research is focused on clinical trials in the field of gynecologic oncology and cancer prevention. She is active as co-investigator on clinical trials for ovarian, endometrial, cervix and vulva cancer. Her area of research is cancer disparity, in particular, cervical cancer health prevention for underscreened populations of women and clinical trial participation for minority patients diagnosed with cancer.

Selected Publications

Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated virus mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Therapy 2005;12:30-38.

Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS Jr, Carson LF. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. Eur J Gynaecol Oncol.2006; 27:231-235.

Chura JC, Marushin R, Boyd A, Ghebre R, Geller MA, Argenta PA. Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: A retrospective analysis and literature review. Gynecol Oncol. 2007;107:79-85.

Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of Thalidomide with Topotecan compared to Topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112;331-339.

Argenta PA, Ormsby RR, Downs LS Jr, Judson PL, Ghebre R, Carson LF. Routine pelvic examination during front line chemotherapy for ovarian cancer: Is there a role? J Reprod Med. 2008;53:3-7.

Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113:205-209.

Geller MA, Ivy J, Dusenbery KE, Ghebre R, Vogel RI, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. Gynecol Oncol. 2010; 118:19-23.

Geller MA, Downs LS, Judson PL, Ghebre R, Argenta PA, Carson LF, Jonson AL, Godfrey K, Isaksson Vogel R, Petzel Sv. Learning about ovarian cancer at the time of diagnosis: Video versus usual care. Gynecol Oncol. 2010;119:370-375.

Geller MA, Cooley S, Argenta PA, Downs LS , Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010; 59:1877-1884.

Subramanian IV, Devineni S, Ghebre R, Ghosh G, Joshi HP, Jing Y, Truskinovsky AM, Ramakrishnan S. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Ther. 2011;18:145-154.

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98-107.

Downs LS Jr, Chura JC, Argenta PA, Judson PL, Ghebre R, Geller MA, Carson LF.  Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial. Gynecol Oncol. 2011;120:265-269.

Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP, Argenta PA. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011;121:112-117.

Ghebre RG, Posthuma R, Vogel RI, Geller MA, Carson LF.  Effect of age and comorbidity on the treatment and survival of elderly patients with vulvar cancer. Gynecol Oncol. 2011;121:595-599.

Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS Jr. A prospective, randomized trial of integrative medicine for women with ovarian cancer. Gynecol Oncol. 2011;123:346-350.